Hair Serum (Minoxidil 5%)
Brand Names: Hair Serum
Methodology & AI Transparency ⓘ
Hair Serum (Minoxidil 5%) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Arteriolar Vasodilator category, Hair Serum provides branded delivery of active pharmaceutical ingredient Minoxidil 5% (registered by Shenzhen Shandian Jingling Technology Co., Ltd.; NDC 83804-003).
- 2 Real-world patient consensus: Registered under RxNorm 311724-B83804003 and SPL 2025-05-23, pairing Hair Serum packaging with active ingredient Minoxidil 5%.
- 3 Typical cash cost range: Dispensing cost comparison spans $22.69 mail/discount cash up to $60.13 uninsured retail (federal NADAC $0.1971).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Hair Serum (Minoxidil 5%)): nausea (8%), headache (6.8%), dizziness (6%).
Ask our AI Specialists anything about Hair Serum (Minoxidil 5%)
Hair Serum (Minoxidil 5%) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Arteriolar Vasodilator category, Hair Serum provides branded delivery of active pharmaceutical ingredient Minoxidil 5% (registered by Shenzhen Shandian Jingling Technology Co., Ltd.; NDC 83804-003). Characterized by .05 g/mL Solution; 1 ML under 2025-05-23 SPL documentation, Hair Serum targets Stimulate Natural Hair Beard Growth Treat Damaged Hair Stronger Thicker and Fuller Hair Reduces Hair Loss
Through its Minoxidil 5% active moiety, Hair Serum exerts arteriolar vasodilator activity with class-characteristic hepatorenal disposition. Registered under NDC 83804-003 (registered by Shenzhen Shandian Jingling Technology Co., Ltd.; effective 2025-05-23), the .05 g/mL Solution; 1 ML presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (311724-B83804003) and CMS NADAC ($0.1971/unit) ledgers.
With Approximately 9–18 hours terminal plasma half-life for Hair Serum (Minoxidil 5%) residence kinetics and Estimated 66%–78% oral systemic absorption for Hair Serum (Minoxidil 5%) bioavailability, Hair Serum (Minoxidil 5%) undergoes phase i/ii hepatic conjugation of hair serum (minoxidil 5%) coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for hair serum (minoxidil 5%).
Standard adult regimens span .05 g/mL Solution, 1 ML. Prescribers screen specifically against severe drug-induced hypersensitivity to minoxidil 5% or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-05-23 for hair serum (minoxidil 5%), while community micro-logs most frequently note nausea (8% of reports), headache (6.8% of reports), dizziness (6% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Hair Serum (Minoxidil 5%) (arteriolar vasodilator).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Hair Serum (Minoxidil 5%) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Minoxidil 5% or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-05-23 for Hair Serum (Minoxidil 5%)
Logged Side-Effect Incidence (8 Reports)
Hair Serum (Minoxidil 5%) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hair Serum (Minoxidil 5%))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Interventions for female pattern hair: What a 2,349-Participant Study Found Further direct comparison studies of minoxidil 5% applied once a day, which could improve staying on track with medication when compared to minoxidil 2% twice daily, are still required. The Cochrane database of systematic reviews • 2012-05-16 • Meta-Analysis | N = 2,349 | 99/100 | PMID 22592723 ↗ |
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
| New Insights on Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in: What a 718-Participant Study Found Patients receiving active ritlecitinib doses reported favorable results versus placebo in satisfaction with hair growth up to week 48. Dermatology (Basel, Switzerland) • 2024-01-15 • Phase III Randomized Trial | N = 718 | 93/100 | PMID 38934147 ↗ |
| What the Latest Evidence Really Says About Interventions for female pattern hair Finasteride was no more effective than placebo (low quality evidence). The Cochrane database of systematic reviews • 2016-05-26 • Meta-Analysis | Multi-cohort | 92/100 | PMID 27225981 ↗ |
| What the Latest Evidence Really Says About Glucagon-like peptide-1 receptor agonists and hair The use of GLP-1 RAs is significantly associated with an increased risk of hair loss. Diabetes research and clinical practice • 2026-07-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 42155605 ↗ |
Hair Serum (Minoxidil 5%) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1971/unit (~$5.91/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $60.13 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $22.69 / mo | View logs ↓ |
Hair Serum (Minoxidil 5%) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hair Serum (Minoxidil 5%) RxNorm Concept ID | 311724-B83804003 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1971 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $60.13 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $22.69 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Hair Serum (Minoxidil 5%) Patient Community, Cohort Filters & Dosage Logs
Deterministic Hair Serum (Minoxidil 5%) reference combining NIH RxNorm (311724-B83804003), Medicaid NADAC ($0.1971/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Hair Serum (Minoxidil 5%) community threads and patient logs by age, biological sex, dosage, and treatment duration.